<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>The Hunger Rebound: What Happens to Your Appetite After Stopping GLP-1 – Élan Clinic</title>
  <meta name="description" content="Weeks 3–6 after stopping GLP-1 medications, appetite can surge with unexpected ferocity. A physician explains the triple hormonal threat — ghrelin, leptin, PYY — and how to navigate it." />
  <link rel="canonical" href="https://elan.clinic/blog/hunger-rebound-after-stopping-glp1.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/hunger-rebound-after-stopping-glp1.html" />
  <meta property="og:title" content="The Hunger Rebound: What Happens to Your Appetite After Stopping GLP-1" />
  <meta property="og:description" content="Weeks 3–6 after stopping GLP-1 medications, appetite surges with ferocity. A physician explains the hormonal storm — ghrelin, leptin, PYY — and how to navigate it." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-02-28" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "The Hunger Rebound: What Happens to Your Appetite After Stopping GLP-1",
    "headline": "The Hunger Rebound: What Happens to Your Appetite After Stopping GLP-1",
    "url": "https://elan.clinic/blog/hunger-rebound-after-stopping-glp1.html",
    "datePublished": "2026-02-28",
    "inLanguage": "en",
    "description": "Weeks 3–6 after stopping GLP-1 medications, appetite can surge with unexpected ferocity. A physician explains the triple hormonal threat — ghrelin, leptin, PYY — and how to navigate it.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Obesity"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/hunger-rebound-after-stopping-glp1.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "Comprehensive review of GLP-1 discontinuation effects",
        "isPartOf": { "@type": "Periodical", "name": "Cureus" },
        "datePublished": "2024"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "Weight rebound meta-analysis: semaglutide vs liraglutide",
        "isPartOf": { "@type": "Periodical", "name": "eClinicalMedicine (The Lancet)" },
        "datePublished": "2025"
      }
    ]
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; font-size: 16px; }
    body { font-family: 'Inter', sans-serif; background-color: #0D1B2A; color: rgba(232, 228, 222, 0.55); line-height: 1.7; -webkit-font-smoothing: antialiased; }
    h1, h2, h3, h4 { font-family: 'Playfair Display', serif; color: #E8E4DE; line-height: 1.2; font-weight: 500; }
    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }
    .container { width: 100%; max-width: 1200px; margin: 0 auto; padding: 0 24px; }
    .label { display: inline-block; font-family: 'Inter', sans-serif; font-size: 0.7rem; font-weight: 600; letter-spacing: 0.18em; text-transform: uppercase; color: #C5A55A; margin-bottom: 20px; }
    .nav { position: fixed; top: 0; left: 0; right: 0; z-index: 100; padding: 20px 24px; display: flex; align-items: center; justify-content: space-between; background: rgba(13, 27, 42, 0.92); backdrop-filter: blur(12px); border-bottom: 1px solid rgba(197, 165, 90, 0.12); }
    .nav__logo { font-family: 'Playfair Display', serif; font-size: 1.25rem; color: #E8E4DE; letter-spacing: 0.06em; text-decoration: none; }
    .nav__logo span { color: #C5A55A; }
    .nav__links { display: flex; align-items: center; gap: 32px; list-style: none; }
    .nav__links a { font-size: 0.78rem; font-weight: 500; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.65); text-decoration: none; transition: color 0.2s; }
    .nav__links a:hover, .nav__links a.active { color: #C5A55A; }
    .breadcrumb { padding: 120px 0 0; background-color: #0D1B2A; }
    .breadcrumb__inner { display: flex; align-items: center; gap: 8px; flex-wrap: wrap; }
    .breadcrumb__item { font-size: 0.75rem; font-weight: 500; letter-spacing: 0.08em; color: rgba(232, 228, 222, 0.4); text-transform: uppercase; }
    .breadcrumb__item a { color: rgba(232, 228, 222, 0.4); text-decoration: none; transition: color 0.2s; }
    .breadcrumb__item a:hover { color: #C5A55A; text-decoration: none; }
    .breadcrumb__sep { font-size: 0.7rem; color: rgba(197, 165, 90, 0.4); }
    .breadcrumb__item--current { color: #C5A55A; }
    .article-header { padding: 48px 0 64px; background-color: #0D1B2A; position: relative; overflow: hidden; }
    .article-header::before { content: ''; position: absolute; top: -100px; right: -150px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%); pointer-events: none; }
    .article-header__content { max-width: 780px; }
    .article-header h1 { font-size: clamp(2rem, 4.5vw, 3.2rem); line-height: 1.15; margin-bottom: 28px; }
    .article-meta { display: flex; align-items: center; flex-wrap: wrap; gap: 24px; padding-top: 24px; border-top: 1px solid rgba(197, 165, 90, 0.15); }
    .article-meta__item { display: flex; align-items: center; gap: 8px; font-size: 0.8rem; color: rgba(232, 228, 222, 0.5); }
    .article-meta__item strong { color: rgba(232, 228, 222, 0.75); font-weight: 500; }
    .article-meta__dot { width: 3px; height: 3px; border-radius: 50%; background: rgba(197, 165, 90, 0.4); }
    .article-body { padding: 0 0 100px; background-color: #0D1B2A; }
    .article-body__inner { max-width: 780px; }
    .article-body p { font-size: 1.05rem; color: rgba(232, 228, 222, 0.72); line-height: 1.85; margin-bottom: 28px; }
    .article-body h2 { font-size: clamp(1.5rem, 2.5vw, 2rem); margin: 56px 0 20px; color: #E8E4DE; }
    .article-body h3 { font-size: clamp(1.1rem, 2vw, 1.35rem); margin: 40px 0 16px; color: #E8E4DE; }
    .article-body strong { color: rgba(232, 228, 222, 0.9); font-weight: 600; }
    .article-body em { color: rgba(232, 228, 222, 0.65); font-style: italic; }
    .article-body hr { border: none; height: 1px; background: rgba(197, 165, 90, 0.15); margin: 48px 0; }
    .pull-quote { border-left: 3px solid #C5A55A; padding: 20px 32px; margin: 40px 0; background: rgba(197, 165, 90, 0.04); }
    .pull-quote p { font-family: 'Playfair Display', serif; font-size: 1.2rem !important; font-style: italic; color: rgba(232, 228, 222, 0.82) !important; line-height: 1.6 !important; margin: 0 !important; }
    .key-stat { background: #111D2E; border: 1px solid rgba(197, 165, 90, 0.18); padding: 32px 36px; margin: 40px 0; }
    .key-stat__number { font-family: 'Playfair Display', serif; font-size: 3rem; color: #C5A55A; line-height: 1; margin-bottom: 8px; }
    .key-stat__label { font-size: 0.88rem; color: rgba(232, 228, 222, 0.6); line-height: 1.5; }
    .timeline { margin: 40px 0; border-left: 2px solid rgba(197, 165, 90, 0.25); padding-left: 28px; }
    .timeline__item { margin-bottom: 32px; position: relative; }
    .timeline__item::before { content: ''; position: absolute; left: -34px; top: 6px; width: 10px; height: 10px; border-radius: 50%; background: #C5A55A; }
    .timeline__period { font-size: 0.78rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: #C5A55A; margin-bottom: 8px; }
    .timeline__desc { font-size: 0.95rem; color: rgba(232, 228, 222, 0.65); line-height: 1.7; }
    .article-sources { margin-top: 60px; padding-top: 32px; border-top: 1px solid rgba(197, 165, 90, 0.12); }
    .article-sources p { font-size: 0.82rem !important; color: rgba(232, 228, 222, 0.38) !important; line-height: 1.6 !important; margin-bottom: 8px !important; }
    .article-sources .sources-label { font-size: 0.7rem; font-weight: 600; letter-spacing: 0.15em; text-transform: uppercase; color: #C5A55A; margin-bottom: 16px; display: block; }
    .back-link { display: inline-flex; align-items: center; gap: 8px; font-size: 0.78rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.5); text-decoration: none; transition: color 0.2s, gap 0.2s; margin-bottom: 60px; }
    .back-link:hover { color: #C5A55A; gap: 12px; text-decoration: none; }
    .footer-cta { background-color: #111D2E; border-top: 1px solid rgba(197, 165, 90, 0.12); text-align: center; padding: 100px 24px; }
    .footer-cta h2 { max-width: 620px; margin: 0 auto 24px; font-size: clamp(1.6rem, 3vw, 2.2rem); }
    .footer-cta__sub { max-width: 480px; margin: 0 auto 40px; font-size: 0.95rem; }
    .btn { display: inline-block; padding: 16px 36px; font-family: 'Inter', sans-serif; font-size: 0.85rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; border: 1.5px solid #C5A55A; color: #C5A55A; background: transparent; cursor: pointer; transition: background 0.2s, color 0.2s; text-decoration: none; }
    .btn:hover { background: #C5A55A; color: #0D1B2A; text-decoration: none; }
    .btn--filled { background: #C5A55A; color: #0D1B2A; }
    .btn--filled:hover { background: #d4b56a; color: #0D1B2A; }
    .footer-legal { background-color: #0D1B2A; border-top: 1px solid rgba(197, 165, 90, 0.08); padding: 40px 24px; }
    .footer-legal__inner { max-width: 1200px; margin: 0 auto; display: flex; flex-direction: column; gap: 8px; }
    .footer-legal p { font-size: 0.75rem; color: rgba(232, 228, 222, 0.3); line-height: 1.6; }
    @media (max-width: 768px) {
      .nav__links { gap: 16px; }
      .nav__links a { font-size: 0.72rem; }
      .breadcrumb { padding-top: 100px; }
      .article-header { padding: 32px 0 48px; }
      .article-body p { font-size: 0.98rem; }
      .pull-quote { padding: 16px 20px; }
    }
  </style>
</head>
<body>

  <!-- ═══ Navigation ══════════════════════════════════════════════════════ -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;display:flex;gap:12px;"><a href="/et.html" style="font-size:0.7rem;">EST</a> <a href="/ukk.html" style="font-size:0.7rem;">FIN</a> <a href="/voprosy.html" style="font-size:0.7rem;">RUS</a></li>
      <li><a href="/#consultation" class="btn" style="padding: 10px 20px; font-size: 0.72rem;">Book a Consultation</a></li>
    </ul>
  </nav>

  <!-- ═══ Breadcrumb ══════════════════════════════════════════════════════ -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">The Hunger Rebound</span>
      </nav>
    </div>
  </div>

  <!-- ═══ Article Header ══════════════════════════════════════════════════ -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Stopping Treatment</span>
        <h1>The Hunger Rebound: What Happens to Your Appetite After Stopping GLP-1.</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-02-28">February 28, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            12 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ═══ Article Body ═════════════════════════════════════════════════════ -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <div class="pull-quote">
          <p>"This is the rebound hunger that comes on strong and relentless a few weeks to a month or 1.5 months off the shot. Often accompanied by the roar of food noise. Absolute misery." — r/GLPGrad (68F, one year off tirzepatide)</p>
        </div>

        <p>
          There is a particular kind of silence that patients on GLP-1 therapy describe. The constant internal negotiation about food — what to eat, when, how much, whether they've had enough — simply goes quiet. One woman put it to me this way: "It's like being near a stream at night and all the chatter is just... gone."
        </p>

        <p>
          For many people, that silence is the most transformative part of treatment. Not the weight lost, not the improved blood pressure or glycaemic markers — the silence.
        </p>

        <p>Which is why its return, when it returns, feels like a catastrophe.</p>

        <p>
          The r/GLPGrad community — tens of thousands of people who have stopped or paused GLP-1 medications — have a name for what happens next. They call it <strong>"The Hunger Games."</strong> A 4-to-8-week period of intense, relentless appetite that descends weeks after stopping, peaks with a ferocity that shocks even experienced patients, and only gradually subsides.
        </p>

        <p>
          This article is about what's happening biologically during that period. Because understanding it matters — not to frighten you, but because what you know you can prepare for, and what you can prepare for you are far less likely to be derailed by.
        </p>

        <hr />

        <h2>What GLP-1 Medications Actually Do to Your Hunger</h2>

        <p>
          To understand the rebound, you first need to understand what these medications are doing while you're on them.
        </p>

        <p>
          GLP-1 receptor agonists like semaglutide and tirzepatide act on multiple systems simultaneously. In the gut, they slow gastric emptying — food leaves the stomach more slowly, so fullness signals are prolonged. In the pancreas, they modulate insulin and glucagon. But the effects most relevant to appetite operate in the brain.
        </p>

        <p>
          GLP-1 receptors are present throughout the hypothalamus — the brain's primary appetite regulation centre — and in the brainstem. Activation of these receptors suppresses ghrelin (the hormone that drives hunger before meals), augments leptin signalling (which tells the brain that fat stores are sufficient), and increases circulating peptide YY (PYY), a satiety hormone released from the gut after eating.
        </p>

        <p>
          The result, for most patients, is not just reduced hunger. It is a fundamental quieting of the neurological noise around food. Meals feel satisfying in ways they didn't before. Impulsive eating becomes easier to resist. Food stops occupying so much mental bandwidth.
        </p>

        <hr />

        <h2>The Triple Threat: What Happens When You Stop</h2>

        <p>
          When GLP-1 therapy is discontinued, the hormonal equilibrium it maintained dissolves — not gradually, but comprehensively, as the drug clears the system over 2–4 weeks.
        </p>

        <p>
          The 2024 comprehensive review published in <em>Cureus</em> (PMC11101251) describes three simultaneous processes that converge to make the post-discontinuation period so physiologically hostile:
        </p>

        <h3>↑ Ghrelin Rebounds</h3>

        <p>
          Ghrelin is produced primarily by cells in the stomach lining. Its levels rise before meals and fall after eating — it is, in the most literal sense, the biological signal of hunger. During weight loss, ghrelin levels increase as part of the body's defence against fat loss: the brain detects reduced fat stores and amplifies hunger signals to drive caloric intake upward.
        </p>

        <p>
          GLP-1 medications suppress ghrelin centrally while in use. When the drug is removed, this suppression lifts. The ghrelin rebound is not merely a return to baseline — it can overshoot, particularly after significant weight loss, as the body aggressively attempts to restore its prior fat stores.
        </p>

        <h3>↓ Leptin Falls</h3>

        <p>
          Leptin is secreted by adipose tissue in proportion to fat mass. More fat means more leptin; less fat means less leptin. When weight loss reduces fat stores, leptin levels fall — and with them, the satiety signal to the hypothalamus. The brain interprets low leptin as a state of starvation risk, regardless of whether any actual nutritional deficit exists.
        </p>

        <p>GLP-1 medications partially compensate for reduced leptin signalling while in use. Post-discontinuation, that compensation disappears, and the low-leptin state is exposed in full.</p>

        <h3>↓ Peptide YY Declines</h3>

        <p>
          PYY is released from the intestines in response to food and signals to the brain that a meal has been satisfying. Weight loss suppresses PYY levels. On GLP-1 therapy, this is partially offset by the drug's direct effects. After stopping, meals simply feel less complete than they did during treatment — even at the same caloric content.
        </p>

        <p>
          The fourth element of this hormonal picture is <strong>reduced metabolic rate</strong>. A lighter body burns fewer calories at rest. The Cell Reports Medicine commentary (2025) found that basal metabolic rate decreases approximately 5% with weight loss, contributing around 40% to the phenomenon of adaptive thermogenesis.
        </p>

        <hr />

        <h2>Why the Rebound Is Worse After More Effective Drugs</h2>

        <p>This is one of the more counterintuitive findings in recent literature, and it deserves attention.</p>

        <p>
          The November 2025 meta-analysis published in <em>eClinicalMedicine</em> (The Lancet) examined weight rebound across multiple GLP-1 medications and found that <strong>semaglutide discontinuation triggered a greater rebound than liraglutide: 8.21 kg versus 4.29 kg</strong> (p=0.008). Semaglutide is also the more effective drug — it produces greater weight loss.
        </p>

        <p>
          The relationship is a dose-response: the deeper the weight loss, the more aggressive the body's compensatory hormonal response upon stopping. The very effectiveness of the treatment creates the conditions for its most disruptive withdrawal.
        </p>

        <div class="pull-quote">
          <p>When these medications work best, stopping them is hardest. This is not a moral or character failing. It is pharmacology.</p>
        </div>

        <hr />

        <h2>The Timeline: Week by Week</h2>

        <div class="timeline">
          <div class="timeline__item">
            <div class="timeline__period">Weeks 1–2: The Quiet Before the Storm</div>
            <div class="timeline__desc">Drug plasma levels are declining but still present. Many patients report little change during this period. Appetite may tick upward slightly. Some describe a mild return of interest in food. This lulls many into thinking the transition will be manageable.</div>
          </div>
          <div class="timeline__item">
            <div class="timeline__period">Weeks 3–6: The Hunger Games</div>
            <div class="timeline__desc">With the drug largely cleared and the full hormonal counter-response now active, hunger can return at an intensity that genuinely shocks patients. The hunger is qualitatively different from ordinary appetite — not the normal rise-and-fall of mealtime hunger, but a sustained, background pressure that doesn't fully resolve with eating. Food noise returns with volume. This is the most dangerous window.</div>
          </div>
          <div class="timeline__item">
            <div class="timeline__period">Weeks 7–12: Gradual Equilibration</div>
            <div class="timeline__desc">For most patients, the acute intensity begins to subside somewhere in this window. The hormonal system has not reset to pre-treatment levels, but the acute rebound peak passes. "If you're struggling with intense hunger after stopping I encourage you to stay the course because it did calm down around the 8–9 week point." — r/GLPGrad</div>
          </div>
          <div class="timeline__item">
            <div class="timeline__period">Month 6+: The New Baseline</div>
            <div class="timeline__desc">A new hormonal equilibrium is established. It is not the same as the pre-treatment state — weight has changed, fat mass is different, and leptin levels reflect that — but the acute crisis has resolved. Patients who built robust habits during treatment are best positioned here.</div>
          </div>
        </div>

        <hr />

        <h2>Why Some People Navigate This Better</h2>

        <p>
          <strong>They built habits during treatment, not after it.</strong> The GLP-1 phase, with its dramatically reduced appetite and quieted food noise, is an extraordinary window to install new eating patterns. Patients who used it to practice protein-first meals, regular resistance training, and conscious eating have a foundation to fall back on when the hormones reassert.
        </p>

        <p>
          <strong>They maintained adequate protein and resistance training throughout.</strong> The case series data (PMC12536186, 2025) showed that lean mass can actually <em>increase</em> during GLP-1-induced weight loss with sufficient protein and resistance training. Preserved muscle mass means a higher resting metabolic rate — which directly reduces the size of the caloric gap that hungry hormones are trying to close after stopping.
        </p>

        <p>
          <strong>They anticipated the Hunger Games.</strong> Forewarned truly is forearmed. Patients who know the week-3-to-6 window is coming, who know it is biological and not a character failure, and who have strategies prepared — distraction, planned meals, accountability — fare meaningfully better than those who are blindsided.
        </p>

        <p>
          <strong>They tapered rather than stopped abruptly.</strong> There are no large RCTs comparing abrupt discontinuation with supervised tapering. But community wisdom and clinical intuition both point toward gradual dose reduction over 2–3 months as a way to give the hormonal system a slower transition.
        </p>

        <hr />

        <h2>What Actually Works: An Evidence-Based Approach</h2>

        <p><strong>Name the wave.</strong> Tell yourself: in weeks 3–6, the hunger will peak. This is temporary. This is biology. Prepare accordingly — plan your meals for that window in advance, arrange accountability, and decide now that you will not make permanent dietary decisions during that period.</p>

        <p><strong>Maintain protein.</strong> Target 1.2–1.6 g per kilogram of body weight per day. Protein has the highest satiety effect per calorie of any macronutrient, and it preserves the lean mass that anchors your metabolic rate.</p>

        <p><strong>Keep resistance training going.</strong> If you weren't doing it during treatment, start now. Three sessions per week is the minimum. Muscle mass is the single most modifiable variable in your metabolic rate after stopping.</p>

        <p><strong>Talk to your physician before stopping, not after.</strong> Supervised tapering, transition planning, and establishing what a re-initiation pathway looks like should all happen in advance.</p>

        <p><strong>Consider whether you need to stop at all.</strong> Oral semaglutide 25 mg received FDA approval for weight management in August 2025. For patients stopping injectable therapy due to cost or access barriers, this may offer a lower-barrier continuation option.</p>

        <hr />

        <h2>Food Noise Returning: The Psychological Reality</h2>

        <p>
          The return of food noise is not just an appetite management challenge. For many patients who spent months experiencing what one described as "the most peaceful relationship with food I've ever had," its return has a grief-like quality.
        </p>

        <p>
          That sense of peace was not an illusion. It was the biological consequence of a medication doing what it was designed to do. Its end does not mean you failed, and it does not mean the transformation was fake. It means the treatment phase has changed, and the maintenance phase requires different tools.
        </p>

        <p>
          The weeks-3-to-6 hunger is not a verdict on your character. Every single person who experiences it is navigating a genuine neurological and endocrine storm. The community has named it. The science has explained it. You do not have to white-knuckle through it alone.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">8.21 kg</div>
          <div class="key-stat__label">Average weight rebound after semaglutide discontinuation, versus 4.29 kg after liraglutide — the more effective the drug, the more aggressive the hormonal response upon stopping. (eClinicalMedicine, 2025)</div>
        </div>

        <!-- ═══ Sources ═══════════════════════════════════════════════════ -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>PMC11101251. "GLP-1 receptor agonist discontinuation: comprehensive review." <em>Cureus</em>, 2024.</p>
          <p>eClinicalMedicine (The Lancet). Weight rebound meta-analysis: semaglutide vs liraglutide, November 2025.</p>
          <p>PMC12535773. "Rebound weight gain after centrally-acting vs gut-acting anti-obesity medications." <em>Cureus</em>, 2025.</p>
          <p>PMC12536186. Body composition case series: GLP-1 therapy with resistance training and protein optimisation, 2025.</p>
          <p>Cell Reports Medicine commentary. "Resistance exercise as co-prescription with GLP-1 therapy," 2025.</p>
        </div>

        <!-- ═══ Back Link ═════════════════════════════════════════════════ -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ═══ Footer CTA ══════════════════════════════════════════════════════ -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>Stopping GLP-1 Therapy? Get a Transition Plan First.</h2>
    <p class="footer-cta__sub">
      A 45-minute consultation to build a structured discontinuation protocol — including tapering strategy, protein targets, and a plan for the Hunger Games window.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ═══ Footer Legal ════════════════════════════════════════════════════ -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
